Patient Monitoring to Change After FDA CAR T-Cell Label Update Approval

The FDA has approved label updates for all currently approved CD19- and BCMA-targeting autologous chimeric antigen receptor (CAR) T-cell therapies. Most significantly, these updates eliminate these agents’ Risk Evaluation and Mitigation Strategy (REMS) programs and streamline the monitoring of patients who receive them as treatment.

Speaking with Blood Cancers Today is Manali Kamdar, MD, an associate professor and the clinical director of lymphoma services at the University of Colorado in Aurora, and lead investigator for the phase 3 TRANSFORM study of lisocabtagene maraleucel for large B cell lymphoma. She gives her expert assessment of the impact that these updates will have on clinical practice.